The outcome of this study could significantly impact Sanofi’s stock performance and investor sentiment, as successful results may position Teplizumab as a leading treatment for Type 1 Diabetes. This ...

Breakthrough T1D International, the leading global type 1 diabetes (T1D) research and advocacy organization, in partnership ...